CASP3 and Parkinson disease: CTS can inhibit the apoptosis of Parkinson’s disease patient-derived human-induced neuronal progenitor cells (PD-hiNPCs) by restoring the membrane potential availability in PD-hiNPCs, reducing the levels of total ROS and mitochondrial ROS, and down-regulating the expression of apoptotic protein caspase-3 (Lee et al., 2020).